紫杉醇脂质体辅助化疗治疗复发转移性乳腺癌的药效评估

The efficacy evaluation of paclitaxel liposome treatment with recurrence or metastasis breast cancer

目的探讨紫杉醇脂质体辅助化疗治疗复发转移性乳腺癌的临床价值。方法将2011年7月至2012年12月纳入研究的92例患者随机分成两组,观察组患者46例,采用紫杉醇脂质体化疗;对照组患者46例,采用紫杉醇化疗。2个疗程后,评估和比较两组患者的近期疗效和不良反应。结果观察组患者单器官转移、≥2个器官转移的化疗总有效率略高于对照组(P>0.05);观察组和对照组患者的过敏反应发生率分别为19.6%和39.1%,观察组患者的过敏反应发生率明显低于对照组(P<0.05)。结论紫杉醇脂质体辅助化疗治疗复发转移性乳腺癌更安全可靠。

Objective To investigate the clinical value of paclitaxel liposome treatment for recur- rence or metastasis breast cancer. Methods The 92 cases of patients admitted to hospital from July 2011 to December 2012 were randomly divided into observation group （n = 46 ） and control group （n = 46）. The observation group was given paclitaxel liposome chemotherapy, and the control group was given paclitaxel chemotherapy. After two courses, the short-term efficacy and chemotherapy adverse reactions in two groups were observed and compared. Results The total effective rate of single organ or ≥2 organ metastasis were not statistically significant between two groups （ P 〉 0. 05 ）. The incidence of allergic reactions in the observation group and the control group were 19. 6% and 39. 10/0 respectively, so the incidence of allergic reactions in the observation group was significantly lower than the control group （ P 〈 0. 05 ）. Conclusions Paclitaxel liposome treatment for recurrence or metastasis breast cancer is more safety and reliable.